Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial

BACKGROUND: During the initial 26-week SPARK (Safety Paediatric efficAcy phaRmacokinetic with Kuvan®) study, addition of sapropterin dihydrochloride (Kuvan®; a synthetic formulation of the natural cofactor for phenylalanine hydroxylase, tetrahydrobiopterin; BH(4)), to a phenylalanine (Phe)-restricte...

Descripción completa

Detalles Bibliográficos
Autores principales: Muntau, Ania C., Burlina, Alberto, Eyskens, François, Freisinger, Peter, Leuzzi, Vincenzo, Sivri, Hatice Serap, Gramer, Gwendolyn, Pazdírková, Renata, Cleary, Maureen, Lotz-Havla, Amelia S., Lane, Paul, Alvarez, Ignacio, Rutsch, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335897/
https://www.ncbi.nlm.nih.gov/pubmed/34344399
http://dx.doi.org/10.1186/s13023-021-01968-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335897/
https://www.ncbi.nlm.nih.gov/pubmed/34344399
http://dx.doi.org/10.1186/s13023-021-01968-1

Ejemplares similares